Вы находитесь на странице: 1из 3

Medica mente 1, 2015 1, 2015 Medica mente

10. Zhao T., Zhang Z.N., Rong Z. Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474: 21215.
11. Okita K., Matsumura Y., Sato Y., Okada A., Morizane A., Okamoto S., Hong H., Nakagawa M., Tanabe K., Tezuka K. et al. A more effi- cient method to generate inte-
[10]. - gration-free human iPS cells. Nat. Methods. 2011; 8: 40912.
. . 1,3 3,0 12. Nikhil S.Stem Cells This Time Without the Cancer. Scientific American News. 2007; 11: 30.
13. Kimbrel E.A., Lanza R. Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov. Oct 2015; 14(10): 68192.
. , . [14]. - 14. Cyranoski D. Japanese Woman Is First Recipient Of Next-Generation Stem Cells. Nature. 2014; n. pag; Web. 6 Mar. 2015.
15. The Japan Times, Kyoto University Hospital To Open Ips Cell Therapy Center In 2019. The Japan Times. N.p., 2015. Web. 7 Mar. 2015.
, - - 16. Park I.H., Arora N, Huo H., Maherali N., Ahfeldt T., Shimamura A. et. al. Disease-specific induced pluripotent stem cells.. Cell. 2008; 134 (5): 87786.
, 2015 ., 17. Freedman B.S., Lam A.Q., Sundsbak J.L., Iatrino R., Su X. et al. Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease
[11]. , - 2019 . - patients with PKD1 mutations. J. JASN October 2013; 24 (10): 157186.
18. Yamanaka S. A fresh look at iPS cells. Cell. 2009; 137: 137.
. , 30 [15]. -
19. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature. 2008; 455: 62732.
( , - KLF4) - , , 20. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Su dhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;
, 20% . , , 463: 103541.
, . . 21. Huang P., He Z., Ji S., Sun H., Xiang D., Liu C., Hu Y., Wang X., Hui L. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature.
2011; 475: 386389.
-. 22. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by
, defined factors. Cell. 2010; 142: 375386.
[12]. . 23. Szabo E., Rampalli S., Risueno R.M., Schnerch A., Mitchell R., FiebigComyn A., Levadoux-Martin M., Bhatia M. Direct conversion of human fibroblasts to multiline-
, - - age blood progenitors. Nature. 2010; 468: 5216.
24. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., Conway S.J., Fu J.D., Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into induced
, , .. , cardiomyocytes. Nature. Published online April 18, 2012.
, . , . ,
- ,
. 2012 . - , ,
. . - . -
, - -
. , -

.
. -
[16, 17]. ,
, , ,
-

, 11 , -
2- [13].
[18].
, -

Advanced Cell Technology (ACT, , )
2010 .
,
. - IN VITRO

.

-
. .
2008 .
( )
, - .. , .. , ...; .. , ...; .. , .. , ..., .; .. , .. , ...
. - [19]. 1 , . .. ,

. , in vitro- 2 , . .. ,

2013 .
, [20], - . -
RIKEN (RIKEN Center for Developmental Biology) [21], [22] - (), ,
. (Kobe City [23].
.
Medical Center General Hospital). - ,
- -
. -. - : , ,
, in situ [24]. , FISH-
. -
70- , .
-
, .
, 2013 .,
,
. -
,

()
. , -
-
, -
, , ,
2014 . - , . -
International Society for Cellular Therapy, [2, 3].
: 1) .
, 2) -
1. Tachibana M., Amato P., Sparman M. et al. Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer. Cell. 2013; 153(6); 122838.
CD73, CD90 CD105 . -
2. Wilmut I., Schnieke A.E., McWhir J., Kind A.J. et al. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997; 385: 8103.
3. Wakayama T., Perry A.C., Zuccotti M., Johnson K.R. et al. Ull-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature. 1998; CD45,
394: 36974. CD34, CD14, CD19 HLA-DR, 3) - , -
4. Zhou Q., Renard J.P., Le Friec G., Brochard V. et al. Generation of fertile cloned rats by regulating oocyte activation. Science. 2003; 302: 1179. [4].
5. Polejaeva I.A., Chen S.H., Vaught T.D., Page R.L. et al. Cloned pigs produced by nuclear transfer from adult somatic cells. Nature. 2000; 407: 8690.
6. Mercer T.R., Neph S., Dinger M.E., Crawford J. et al. The human mitochondrial transcriptome. Cell. 2011; 146: 64558.
(, , - ,
7. Koilkonda R.D., Guy J. Lebers hereditary optic neuropathy-gene therapy: From benchtop to bedside. J Ophthalmol. 2011; 179412. -) [1]. -
8. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 66376. . , V. Sabapathy .
9. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined , -
factors. Cell/ 2007; 131: 86172.
, [2]. (25 ) [5].
10 11
Medica mente 1, 2015 1, 2015 Medica mente


. ,
1. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent
, . mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 3157.
1012 - 2. Eaves C.J. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood. 2015 Apr 23; 125(17): 260513.
[4]. - G-- 3. Mndez-Ferrer S., Scadden D.T., Snchez-Aguilera A. Bone marrow stem cells: current and emerging concepts. Ann N Y Acad Sci. 2015 Jan; 1335: 3244.
- . , 4. Roselli E.A., Lazzati S., Iseppon F., Manganini M., Marcato L., Gariboldi M.B., Maggi F., Grati F.R., Simoni G. Fetal mesenchymal stromal cells from cryopre-
served human chorionic villi: cytogenetic and molecular analysis of genome stability in long-term cultures. Cytotherapy. 2013 Nov; 15(11): 134051.
in vitro , - G- -
5. Sabapathy V., Sundaram B., Mankuzhy P., Kumar S. Human Whartons Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with
. . - hair growth. PLoS One. 2014 Apr 15; 9(4): e93726.
FISH 6. Guidelines for the Clinical Translation of Stem Cells, International Society forStem Cell Research. 2008: 119.
, (fluorescent in situ hybridization) - 7. Mayshar Y., Ben-David U., Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E., Benvenisty N. Identification and classification of chromosomal
aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010; 7: 52131.
. - .
8. Amps K., Andrews P.W., Anyfantis G., Armstrong L., Avery S., Baharvand H., Baker J., Baker D., Munoz M.B., Beil S. et al. Screening ethnically diverse human embryonic
, - stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011; 29:113244.
, , 9. Wang Y., Zhang Z., Chi Y., Zhang Q., Xu F. et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malig-
, , nant transformation. Cell Death Dis. 2013 Dec 5; 4: e950.
. - , . 10. Kim J.A., Im K.O., Park S.N., Kwon J.S. et al. Cytogenetic heterogeneity and their serial dynamic changes during acquisition of cytogenetic aberrations in cul-
tured mesenchymal stem cells. Mutat Res. 2015 Jul; 777: 608.
, -
, , . ,
array-
, - CGH .
, , , J.-A. Kim .
. 7

( )
FISH , -
7
(Guidelines for the Clinical Translation of Stem Cells), ( FISH).
- ,
.. , ...; .. , ...; .. , ..
(the International Society for Stem Cell Research). 7, -
- ,
. .. ,
, , 7 [10]. -
- , FISH- -
[6]. -
.
. -
.
. - : -
- . ,
- ? J.-A. Kim ., ,
G-, G-- , ,
. , - (46,XY,der(7)dup(7)(q32q36)t(7;?)(q36;?)[1]/46,XY[14]) .
, .
. ,
, 7
: , , , -
, (46,XY,der(7)dup(7)(q32q36)t(7;?)(q36;?) [20]) - ,
1, 12, 17 20, - 16- [10].
. , , ,
, N. Benvenisty . - 4 14
, [2, 5, 4]. -
104 , 66 14 19, - (NBS)
38 - - , NBS1 5 6 NBS1 657
, 18 - [4]. , - del 5 657661 del . NBS1
. ~20% , , , - 90% ,
~9% [7]. - - [1, 2, 4]. -
P.W. Andrews . - - [1, 2, 4]. NBS 23--
34% 129 [8]. , . 10 - , - : O, , ,
, - 200 - 1981 . , , -
, 20 54%. , C. Weemaes [7]. : ,
Y. Wang . 9 , , , - .
3 30 : . CD3+, CD19+,
, 7 1 [4]. : , , - CD4+, CD4+/CD8+, IgA, IgG,
(CNV) , - , . IgG2. -
10 . - - - [5, NBS 50 , -
- . 6]. , 1000 [7, 8].
, 8 1998 . NBS1 [4]. ,
, 20 : , -
[9]. , . , - , . -
12 13
Medica mente 1, 2015 1, 2015 Medica mente


. ,
1. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent
, . mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 3157.
1012 - 2. Eaves C.J. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood. 2015 Apr 23; 125(17): 260513.
[4]. - G-- 3. Mndez-Ferrer S., Scadden D.T., Snchez-Aguilera A. Bone marrow stem cells: current and emerging concepts. Ann N Y Acad Sci. 2015 Jan; 1335: 3244.
- . , 4. Roselli E.A., Lazzati S., Iseppon F., Manganini M., Marcato L., Gariboldi M.B., Maggi F., Grati F.R., Simoni G. Fetal mesenchymal stromal cells from cryopre-
served human chorionic villi: cytogenetic and molecular analysis of genome stability in long-term cultures. Cytotherapy. 2013 Nov; 15(11): 134051.
in vitro , - G- -
5. Sabapathy V., Sundaram B., Mankuzhy P., Kumar S. Human Whartons Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with
. . - hair growth. PLoS One. 2014 Apr 15; 9(4): e93726.
FISH 6. Guidelines for the Clinical Translation of Stem Cells, International Society forStem Cell Research. 2008: 119.
, (fluorescent in situ hybridization) - 7. Mayshar Y., Ben-David U., Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E., Benvenisty N. Identification and classification of chromosomal
aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010; 7: 52131.
. - .
8. Amps K., Andrews P.W., Anyfantis G., Armstrong L., Avery S., Baharvand H., Baker J., Baker D., Munoz M.B., Beil S. et al. Screening ethnically diverse human embryonic
, - stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011; 29:113244.
, , 9. Wang Y., Zhang Z., Chi Y., Zhang Q., Xu F. et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malig-
, , nant transformation. Cell Death Dis. 2013 Dec 5; 4: e950.
. - , . 10. Kim J.A., Im K.O., Park S.N., Kwon J.S. et al. Cytogenetic heterogeneity and their serial dynamic changes during acquisition of cytogenetic aberrations in cul-
tured mesenchymal stem cells. Mutat Res. 2015 Jul; 777: 608.
, -
, , . ,
array-
, - CGH .
, , , J.-A. Kim .
. 7

( )
FISH , -
7
(Guidelines for the Clinical Translation of Stem Cells), ( FISH).
- ,
.. , ...; .. , ...; .. , ..
(the International Society for Stem Cell Research). 7, -
- ,
. .. ,
, , 7 [10]. -
- , FISH- -
[6]. -
.
. -
.
. - : -
- . ,
- ? J.-A. Kim ., ,
G-, G-- , ,
. , - (46,XY,der(7)dup(7)(q32q36)t(7;?)(q36;?)[1]/46,XY[14]) .
, .
. ,
, 7
: , , , -
, (46,XY,der(7)dup(7)(q32q36)t(7;?)(q36;?) [20]) - ,
1, 12, 17 20, - 16- [10].
. , , ,
, N. Benvenisty . - 4 14
, [2, 5, 4]. -
104 , 66 14 19, - (NBS)
38 - - , NBS1 5 6 NBS1 657
, 18 - [4]. , - del 5 657661 del . NBS1
. ~20% , , , - 90% ,
~9% [7]. - - [1, 2, 4]. -
P.W. Andrews . - - [1, 2, 4]. NBS 23--
34% 129 [8]. , . 10 - , - : O, , ,
, - 200 - 1981 . , , -
, 20 54%. , C. Weemaes [7]. : ,
Y. Wang . 9 , , , - .
3 30 : . CD3+, CD19+,
, 7 1 [4]. : , , - CD4+, CD4+/CD8+, IgA, IgG,
(CNV) , - , . IgG2. -
10 . - - - [5, NBS 50 , -
- . 6]. , 1000 [7, 8].
, 8 1998 . NBS1 [4]. ,
, 20 : , -
[9]. , . , - , . -
12 13